Medicines – Open-House Biologics Rebate Agreements 2025-32 - Golimumab

Summary

The tender concerns rebate agreements for medicines containing the active substance golimumab under an open procedure. All suitable pharmaceutical companies may conclude the agreement under uniform conditions; no individual negotiations are held and no exclusivity is granted. The contract term is up to 24 months starting on 01/12/2025 and ends no later than 30/11/2027. The detailed participation and contract conditions must be checked in the tender documents.